AbbVie: ‘We Looked At Biosimilars, We Are Not Interested’
Originator Prefers Using Manufacturing Capacity For Branded Drugs
AbbVie spoke about past musings to enter the biosimilar space like its competitors, including Amgen and Pfizer, as it gears up for the launch of the first biosimilar to its own Humira blockbuster at the end of January 2023.
